A new study at Moffitt Cancer Center could offer hope to people with melanoma, the deadliest form of skin cancer.
Researchers are investigating whether an injectable known as PV-10 can shrink tumors and reduce the spread of cancer. PV-10 is a solution developed from Rose Bengal, a water-soluble dye commonly used to stain damaged cells in the eye. Early clinical trials show PV-10 can boost immune response in melanoma tumors, as well as the blood stream.
“Various injection therapies for melanoma have been examined over the past 40 years, but few have shown the promising results we are seeing with PV-10,” said Shari Pilon-Thomas, Ph.D., assistant member of Moffitt’sImmunology Program.
In the initial study, researchers injected a single dose of PV-10 into mice with melanoma. The result was a significant reduction in the skin cancer lesions, as well as a sizable reduction in melanoma tumors that had spread to the lungs. The researchers said the dye solution appeared to produce a robust anti-tumor immune response and may be safer than existing immunological agents.
“We are currently in the middle of our first human clinical trial of PV-10 for advanced melanoma patients. In addition to monitoring the response of injected melanoma tumors, we are also measuring the boost in the anti-tumor immune cells of patients after injection,” explained Amod A. Sarnaik, M.D., assistant member of Moffitt’s Cutaneous Oncology Program.
The Latest on: Melanoma
- Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Dealon November 21, 2019 at 4:03 pm
Bristol-Myers Squibb Company BMY announced that the phase III study evaluating a combination of Opdivo plus Yervoy in patients with resected high-risk melanoma missed one of the co-primary endpoints.
- Metastatic Melanoma Study Mixed Results Could Be a Positiveon November 21, 2019 at 1:30 pm
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced results from a subgroup analysis of metastatic melanoma patients in its Phase 2 study of lifileucel. These results were released in an abstract ...
- RDK Melanoma Foundation: Keeping public safe from sunon November 21, 2019 at 11:55 am
What does the Richard David Kann Melanoma Foundation do? The Richard David Kann (RDK) Melanoma Foundation has been working locally and nationally since its inception to save lives by changing ...
- Bald Model That Rihanna Made Famous, Slick Woods Confirms She Is Battling Stage 3 Melanomaon November 21, 2019 at 10:55 am
The 23-year-old model with a boisterous personality posted a photo of herself partying with friends with the caption reading, “How I feel about chemotherapy, shout out to everyone that gotta go ...
- Rochester cancer-therapy firm to collaborate with drugmaker on melanoma treatmenton November 21, 2019 at 9:25 am
Vyriad, a company in southeastern Minnesota that is designing viruses to selectively kill cancer cells, has signed a major agreement with the biotech drugmaker Regeneron to collaborate on drug ...
- How much sunshine causes melanoma? It's in your geneson November 21, 2019 at 6:46 am
Australian researchers from QIMR Berghofer Medical Research Institute have shown that 22 different genes help to determine how much sun exposure a person needs to receive before developing melanoma.
- Iovance +4.5% after new data on lifileucel melanoma studyon November 21, 2019 at 4:55 am
Iovance Biotherapeutics (NASDAQ:IOVA) jumps 4.5% in premarket trading after reporting 41% objective response rate in 42 patients in Cohort 2 of Phase 2 lifileucel metastatic melanoma study C-144-01 in ...
- Rochester cancer therapy firm to collaborate with drugment on melanoma treatmenton November 20, 2019 at 10:23 am
Vyriad, a company in southeastern Minnesota that is designing viruses to selectively kill cancer cells, has signed a major agreement with the biotech drugmaker Regeneron to collaborate on a drug ...
- Bristol's Opdivo-Yervoy combo fails to top Opdivo in adjuvant melanomaon November 20, 2019 at 7:11 am
Bristol-Myers Squibb’s Opdivo-Yervoy combo has changed the game in late-stage melanoma, but it's hit a roadblock in expanding to post-surgery treatment. In patients with advanced cancer but no ...
- Phase 1/2 Clinical Trial Data for IDE196 Presented at Society for Melanoma Research Congresson November 20, 2019 at 3:36 am
Robust enrollment, with 27 total patients enrolled in the Phase 1 dose escalation portion, including 12 patients in MUM DLT cohorts, 14 patients in MUM overflow cohort, and 1 GNA11 cutaneous melanoma ...
via Google News and Bing News